SARS-CoV-2: Difference between revisions
From IDWiki
No edit summary |
(→) |
||
Line 15: | Line 15: | ||
*Secondary household attack rate of 12-17% |
*Secondary household attack rate of 12-17% |
||
=== |
===Risk Factors for Mortality=== |
||
* |
*Greater age |
||
* |
*Male sex |
||
* |
*[[COPD]] |
||
* |
*[[Dyslipidemia]] |
||
* |
*[[Diabetes]] |
||
==Clinical Manifestations== |
==Clinical Manifestations== |
||
Line 31: | Line 31: | ||
*Viral load detectable before symptom onset and peaks around the time of symptom onset |
*Viral load detectable before symptom onset and peaks around the time of symptom onset |
||
=== |
===Complications=== |
||
* |
*In critically ill patients: |
||
** |
**[[ARDS]] (75%) |
||
** |
**[[AKI]] (40%) |
||
** |
**[[Thrombosis]] (10%) |
||
== |
==Diagnosis== |
||
* |
*PCR from NP swab |
||
** |
**May be positive long after no longer infectious |
||
==Management== |
==Management== |
||
Line 48: | Line 48: | ||
*Investigational therapeutics include [[tocilizumab]], [[lopinavir/ritonavir]], and [[chloroquine]] |
*Investigational therapeutics include [[tocilizumab]], [[lopinavir/ritonavir]], and [[chloroquine]] |
||
== |
==Further Reading== |
||
*Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. ''JAMA''. doi: [https://doi.org/10.1001/jama.2020.12839 10.1001/jama.2020.12839] |
|||
* 10.1001/jama.2020.12839 |
|||
[[Category:Viruses]] |
[[Category:Viruses]] |
Revision as of 23:23, 30 July 2020
Background
Microbiology
- Coronavirus related to SARS-CoV
- Virion consists of:
- Spike glycoprotein (S)
- Membrane protein (M)
- Nucleocapsid protein (N)
- Hemagglutinin esterase (He)
- Envelope protein (E)
Epidemiology
- First cases detected Dec 2019 related to likely exposure in wet market in Wuhan, Hubei, China, and declared a pandemic in 2020
- Secondary household attack rate of 12-17%
Risk Factors for Mortality
- Greater age
- Male sex
- COPD
- Dyslipidemia
- Diabetes
Clinical Manifestations
- Incubation period 4-5 days (range 2 to 11), possibly as long as 14 days in some cases
- Main presenting symptoms were fever and cough, followed by myalgia, fatigue, headache, dyspnea
- Other symptoms include dyspnea, rhinorrhea, vomiting, diarrhea, anosmia/hyposmia
- Lymphopenia is common, as is hypoalbuminemia, elevated D-dimer, CRP, LDH, AST/ALT
- Viral load detectable before symptom onset and peaks around the time of symptom onset
Complications
- In critically ill patients:
- ARDS (75%)
- AKI (40%)
- Thrombosis (10%)
Diagnosis
- PCR from NP swab
- May be positive long after no longer infectious
Management
- Dexamethasone for patients requiring supplemental oxygen
- Investigational therapeutics include tocilizumab, lopinavir/ritonavir, and chloroquine
Further Reading
- Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA. doi: 10.1001/jama.2020.12839